

# Targeting cognitive Impairment in MDD

Atul R. Mahableshwarkar

---

# Disclosures

---

- Full time employee of Takeda Development Center Americas Inc.
- Own stock in GlaxoSmithKline, Johnson & Johnson and Pfizer

# Definitions of Cognitive Impairment in MDD

---


- DSM-III
  - Complains or evidence of diminished ability to think or concentrate, such as slowed thinking, or indecisiveness not associated with marked loosening of associations or coherence
- DSM-III-R
  - Diminished ability to think or concentrate, or indecisiveness nearly every day (either by subjective account or as observed by others)

# Definitions of Cognitive Impairment in MDD


---

- DSM-IV
  - No change from previous definition
- DSM-5
  - No change from previous definition

# Cognitive impairment: Magnitude




# Employment Status



*Ellis et al Int Psychogeriatr.*  
2009. 21, 672-687

*Pietrzak et al. J Clin Exp*  
*Neuropsych* 2009; 1-12

*Maruff et al ECNP*  
2013



Major depression  
(treated)  
(n=564)

0.05% BAC  
healthy adults  
(n=32)

24 hours awake  
healthy adults  
(n=32)

*Maruff et al ECNP  
2013*

*Falleti et al. J. Sleep Res.  
(2003) 12, 265–274*

*Falleti et al. J. Sleep Res.  
(2003) 12, 265–274*